Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer

Rhea-AI Summary

Janux Therapeutics (NASDAQ: JANX) has promoted Dr. Zachariah McIver to Chief Medical Officer. Dr. McIver, a physician-scientist with over 20 years of clinical research experience, previously served as Amgen's Executive Medical Director for more than 4 years, where he led BiTE assets development across multiple cancer types.

The company is developing immunotherapies through its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms. Their clinical pipeline includes JANX007, a TRACTr targeting PSMA in Phase 1 trials for mCRPC patients, and JANX008, a TRACTr targeting EGFR in Phase 1 trials for multiple solid cancers including colorectal, head and neck, lung, renal, and breast cancers.

Positive

• Two products in Phase 1 clinical trials: JANX007 and JANX008
• Appointment of experienced CMO with relevant expertise in T cell engagers
• Multiple TRACTr and TRACIr candidates in development pipeline

Negative

• None.

SAN DIEGO--(BUSINESS WIRE)-- Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today announced the promotion of Dr. Zachariah McIver to Chief Medical Officer.

“The appointment of Zach to CMO is an important milestone for Janux. Zach’s expertise in T cell engagers has brought significant value to our organization and he has been essential in our efforts to optimize the clinical development of our PSMA-TRACTr and clinical pipeline,” said David Campbell, Ph.D., President and CEO of Janux. “We are excited for Zach’s continued contributions which we believe will have a tremendous impact on the patients we treat.”

An accomplished physician-scientist with over 20 years of experience in clinical research, Dr. McIver joined Janux after serving as Amgen’s Executive Medical Director for over 4 years, leading cross-functional teams in the design, implementation, and execution of clinical and correlative study strategies. During his time at Amgen, Dr. McIver led the efforts in maximizing the value of bispecific T-cell engager (BiTE) assets across multiple hematologic and solid tumor malignancies.

Dr. McIver earned a B.S. in Physics and General Sciences from the University of Oregon, a Medical Doctorate (D.O.) from Ohio University College of Osteopathic Medicine and a Ph.D. in Molecular Medicine and Translational Sciences at the Wake Forest University School of Medicine. He completed his internal medicine residency at the Cleveland Clinic, and his clinical fellowship in hematology and oncology at the National Heart, Lung, and Blood Institute (NHLBI) at the National Institutes of Health (NIH).

Janux’s TRACTr and TRACIr Pipeline

Janux’s first clinical candidate, JANX007, is a TRACTr that targets prostate-specific membrane antigen (PSMA) and is being investigated in a Phase 1 clinical trial in adult patients with mCRPC. Janux’s second clinical candidate, JANX008, is a TRACTr that targets epidermal growth factor receptor (EGFR) and is being studied in a Phase 1 clinical trial for the treatment of multiple solid cancers including colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. We are also generating a number of additional TRACTr and TRACIr programs for potential future development, some of which are at development candidate stage or later. We are currently assessing priorities in our preclinical pipeline.

About Janux Therapeutics

Janux is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Janux’s proprietary technology enabled the development of two distinct bispecific platforms: TRACTr and TRACIr. The goal of both platforms is to provide cancer patients with safe and effective therapeutics that direct and guide their immune system to eradicate tumors while minimizing safety concerns. Janux is currently developing a broad pipeline of TRACTr and TRACIr therapeutics directed at several targets to treat solid tumors. Janux has two TRACTr therapeutic candidates in clinical trials, the first targeting PSMA is in development for prostate cancer, and the second targeting EGFR is being developed for colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. For more information, please visit www.januxrx.com and follow us on LinkedIn.

Forward-Looking Statements

This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Janux’s ability to bring new treatments to cancer patients in need, expectations regarding the timing, scope and results of Janux’s development activities, including its ongoing and planned preclinical studies and clinical trials, the potential benefits of Janux’s product candidates and platform technologies, and expectations regarding the use of Janux’s platform technologies to generate novel product candidates. Factors that may cause actual results to differ materially include the risk that compounds that appear promising in early research do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Janux may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Janux faces, please refer to Janux’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov. Such forward-looking statements are current only as of the date they are made, and Janux assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250124127364/en/

Investors:

Andy Meyer

Janux Therapeutics

ameyer@januxrx.com

(202) 215-2579

Media:

Jessica Yingling, Ph.D.

Little Dog Communications Inc.

jessica@litldog.com

(858) 344-8091

Source: Janux Therapeutics

FAQ

What are Janux Therapeutics' (JANX) main clinical candidates in development?

Janux has two main clinical candidates: JANX007, a PSMA-targeting TRACTr in Phase 1 trials for mCRPC, and JANX008, an EGFR-targeting TRACTr in Phase 1 trials for multiple solid cancers.

What types of cancer is JANX008 being tested for in Phase 1 trials?

JANX008 is being tested for colorectal carcinoma, head and neck squamous cell carcinoma, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma, and triple-negative breast cancer.

What is Dr. Zachariah McIver's background before joining Janux as CMO?

Dr. McIver previously served as Amgen's Executive Medical Director for over 4 years, leading BiTE assets development. He has over 20 years of clinical research experience and holds degrees from University of Oregon, Ohio University, and Wake Forest University.

What are the main technology platforms used by Janux Therapeutics (JANX)?

Janux utilizes two proprietary platforms: the Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms for developing immunotherapies.